The Aesthetics Boom Has a Winner. You've Been Looking at the Wrong Layer.

A Charlotte cosmetic surgery practice just partnered with Aesthetic Partners, a private equity-backed platform building a portfolio of aesthetic clinics. The deal was announced through a M&A advisory firm with the kind of press release you'd expect from any of the dozens of similar transactions happening right now across the country.

If you're looking for a stock to buy based on this news, you've been pointed in the wrong direction. Aesthetic Partners is private. Graper Harper Cosmetic Surgery is a small Charlotte practice. There is no ticker involved.

But there is a ticker that benefits from every single one of these deals. The question is whether you've been looking at the wrong layer of the business.

The consolidation story has no public face

Private equity has flooded into medical aesthetics. Market research firms estimate the global aesthetic medicine market topped $100 billion in 2025 and is projected to reach $240–250 billion by the end of the decade at roughly 10% annual growth. The medical spa segment alone is expected to grow from $21 billion in 2025 to $24 billion in 2026 at a 14% rate.

The response has been a wave of rollup platforms. In the past two years, firms including Athenix, Alpha Aesthetics Partners, Advanced Medaesthetic Partners, Ascend Plastic Surgery Partners, Olympus Cosmetic Group, and United Aesthetic Alliance have entered the market, each backed by private equity sponsors. Aesthetic Partners—the one that just closed with Graper Harper—partnered with Norwest, a major investment firm, in November 2023 to fuel expansion.

Dozens of platforms are competing to buy independently owned plastic surgery practices and med spas that have historically been solo-physician operations. The industry remains heavily fragmented, which is precisely why private equity sees opportunity: consolidation, operating leverage, shared marketing, standardized pricing, and centralized purchasing all create margin improvement in theory.

But none of these platforms is publicly traded. You cannot buy the consolidation story directly.

The layer you can own

The publicly traded investor has one real option for capturing the aesthetics boom, and it sits inside a stock most people think of as a pharmaceutical and immunology company: AbbVie (ABBV).

When AbbVie acquired Allergan in 2020, it also acquired Allergan Aesthetics—owner of Botox, Juvéderm, Voluma, and Azzalure, among other products. Those products are what every single one of those newly consolidated practices injects into their patients. Whether Dr. Harper runs his practice independently or as part of Aesthetic Partners, the patient still needs Botox. The practice still needs to buy it from AbbVie.

AbbVie reported full-year net revenues of $61.2 billion in 2025. Allergan Aesthetics generated $4.7 billion that year, up 12% from the prior period. In the first quarter of 2026, Botox Therapeutic net revenues reached $1.0 billion, up 16.5% on a reported basis.

The product companies are not just participating in the aesthetics boom. They are the tollbooth.

The product company advantage

Here is the economics question the consolidation headlines don't address: who has the better margins?

A med spa or cosmetic surgery practice buys Botox from AbbVie at wholesale cost, pays for the injector's time, the facility, the marketing, the overhead, and the patient acquisition. The product manufacturer has already absorbed R&D, FDA approval, and manufacturing at scale. The incremental cost of filling another syringe is tiny. The margin profile of the product supplier dwarfs that of the treatment provider.

This is not theoretical. AbbVie trades at a market cap of roughly $461 billion with trailing earnings around $64 billion—giving it a P/E of about 73, high but supported by a dividend yield of 2.6% and a broad revenue base spanning immunology, aesthetics, neuroscience, and eye care. The aesthetics segment is not AbbVie's largest business, but it is one of its most durable. Botox benefits from a regulatory moat, switching costs for physicians trained on the product, and patient brand recognition that no competitor has matched at scale.

Meanwhile, the rollup platforms are fighting a margin war. Industry guides from 2026 note that percentage-of-production compensation plans for injectors can create weak contribution margins once product costs, discounts, and support staff are accounted for. Provider turnover is a persistent risk—if the high-producing injector leaves, the patients may leave with them. Key-person dependency, compliance gaps, and state-by-state medical ownership rules make operating leverage harder to achieve than the pitch decks suggest.

The platforms are buying practices at inflated multiples. A 2026 med spa M&A multiples report documents the premium valuations sellers command in this competitive environment. The platforms will have to demonstrate execution to justify those prices. The product manufacturer just has to sell its product—which it does regardless of who owns the practice on the other end.

Who actually wins the aesthetics boom

Consider the chain of value creation:

The patient sits in a chair. The injector uses a product. The product was manufactured and patented by a company like AbbVie, Galderma, or Revance. The injector works for a practice that may or may not be owned by a PE-backed rollup. The rollup pays interest on the debt it used to buy the practice. The product manufacturer collects revenue from every practice, every injector, every patient—with no exposure to provider turnover, no compliance headaches, and no patient acquisition costs.

This is the wrong metric trap. The industry measures consolidation by number of acquisitions, platforms formed, or procedures performed. The investor metric should be: where is the economic rent? Where is the pricing power? Where is the business that makes money regardless of the consolidation cycle?

The answer is upstream, at the product manufacturers.

What this means for the investor

You cannot buy Aesthetic Partners. You cannot buy any of the dozens of PE-backed aesthetic platforms forming right now. They are private companies whose investors will see their returns—in five to seven years, if at all—through a sale, an IPO, or a recapitalization.

The publicly traded exposure to the aesthetics boom exists in a narrower set of companies. AbbVie is the most visible, with its Allergan Aesthetics portfolio generating $4.7 billion annually and growing. Revance Therapeutics (RVNC) operates in the aesthetic biotech space but is a smaller, riskier play with a volatile stock. Galderma is majority-owned by Sanofi and Nestlé and trades through those parent companies rather than independently.

AbbVie's aesthetics business is not the only reason to own AbbVie—but it is the part of AbbVie that benefits directly from every press release announcing another practice sale, another rollup platform, another consolidated clinic. The boom in cosmetic procedures translates directly into more product sales. The consolidation doesn't help the platforms as much as it helps the people selling to them.

The consensus story is about which practice gets bought and which platform grows fastest. The investor consequence is that the companies selling the product to all of them may be the ones with the most predictable economic upside. You don't need to be right about which platform wins. You just need the boom to happen—and the evidence suggests it already is.